490 filings
ARS
2023 FY
VKTX
Viking Therapeutics Inc
5 Apr 24
Annual report to shareholders
4:15pm
DEFA14A
VKTX
Viking Therapeutics Inc
5 Apr 24
Additional proxy soliciting materials
4:10pm
DEF 14A
VKTX
Viking Therapeutics Inc
Definitive proxy
5 Apr 24
4:05pm
4
Marianna Mancini
27 Mar 24
Viking Therapeutics / Marianna Mancini ownership change
8:52pm
4
Lian Brian
27 Mar 24
Viking Therapeutics / Brian Lian ownership change
8:51pm
4
pgwju rc8
27 Mar 24
Viking Therapeutics / GREG ZANTE ownership change
8:50pm
8-K
huwnfpj0
26 Mar 24
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
7:08am
4
3h9z67kop0h576 olcd
4 Mar 24
Viking Therapeutics / Brian Lian ownership change
7:54pm
4
pidp hexhhw4s2f2re8x
4 Mar 24
Viking Therapeutics / Marianna Mancini ownership change
7:52pm
4
ywgd0oly
4 Mar 24
Viking Therapeutics / GREG ZANTE ownership change
7:50pm
8-K
anrl0d
4 Mar 24
Other Events
4:52pm
424B5
59bqox3iotw5oc31ccat
1 Mar 24
Prospectus supplement for primary offering
4:13pm
8-K
reyumx2qv 03kt
1 Mar 24
Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock
4:05pm
424B5
pqph1xg
27 Feb 24
Prospectus supplement for primary offering
5:21pm
8-K
whihh2jl0wnrscsn h6z
27 Feb 24
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
7:04am
SC 13G/A
y7k22 zncm
14 Feb 24
Viking Therapeutics / VIKING GLOBAL INVESTORS ownership change
10:13am
SC 13G
b83afsxx
13 Feb 24
Viking Therapeutics / VANGUARD ownership change
5:17pm
4
it5sj84tmf057fth
9 Feb 24
Viking Therapeutics / Brian Lian ownership change
8:59pm
144
jxvwy7kkzkx0wp0gst
9 Feb 24
Notice of proposed sale of securities
4:01pm
SC 13G/A
j6wnlsad7rysjo
9 Feb 24
Viking Therapeutics / FMR ownership change
10:05am